Xie Qing-Yu, Liu Hai-Yan, Guo Ze-Yi, Wu Yan-Ping, He Guo-Lin, Cai Lei, Pan Ming-Xin, Fu Shun-Jun
Department of Hepatobiliary Surgery II, General Surgery Center, Guangdong Provincial Research Center for Artificial Organ and Tissue Engineering, Guangzhou Clinical Research and Transformation Center for Artificial Liver, Institute of Regenerative Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Front Mol Biosci. 2022 Feb 4;8:810251. doi: 10.3389/fmolb.2021.810251. eCollection 2021.
Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed malignancy and the third leading cause of cancer-related deaths worldwide. A 58-year-old man visited his local hospital due to abdominal discomfort and was diagnosed with lung metastasis. After admission to our hospital in April 2020, he received two cycles of transcatheter arterial embolization (TAE), hepatic arterial infusion chemotherapy (HAIC-Folfox), sorafenib, and camrelizumab every 3 weeks. Due to the end of HAIC treatment, he underwent drug-eluting transcatheter arterial chemoembolization (dTACE) once, sorafenib, and camrelizumab. However, because of worsening liver function, we interrupted TACE and only gave sorafenib and camrelizumab in August 2020. Although he received systemic therapy, the tumors still rapidly progressed and we considered the possibility of tumor resistance. Subsequently, regorafenib was given. In September, the patient underwent conventional TACE (cTACE) once, regorafenib, and camrelizumab. After half a year of comprehensive treatment, the treatment effect was not satisfactory, and he returned to the local hospital to received regorafenib every day and camrelizumab once every 3 weeks. The patient found that the tumor and lung metastasis had shrunk significantly after 1 year of the initial diagnosis, then he was admitted to our hospital and received surgery treatment, and now he has survived disease-free for 6 months.
肝细胞癌（HCC）是全球第六大最常被诊断出的恶性肿瘤，也是癌症相关死亡的第三大主要原因。一名58岁男性因腹部不适前往当地医院就诊，被诊断为肺转移。2020年4月入院后，他每3周接受两个周期的经动脉化疗栓塞术（TAE）、肝动脉灌注化疗（HAIC-Folfox）、索拉非尼和卡瑞利珠单抗治疗。由于HAIC治疗结束，他接受了一次药物洗脱经动脉化疗栓塞术（dTACE）、索拉非尼和卡瑞利珠单抗治疗。然而，由于肝功能恶化，我们于2020年8月中断了TACE治疗，仅给予索拉非尼和卡瑞利珠单抗治疗。尽管他接受了全身治疗，但肿瘤仍迅速进展，我们考虑了肿瘤耐药的可能性。随后给予了瑞戈非尼治疗。9月，患者接受了一次传统TACE（cTACE）、瑞戈非尼和卡瑞利珠单抗治疗。经过半年的综合治疗，治疗效果并不理想，他返回当地医院，每天接受瑞戈非尼治疗，每3周接受一次卡瑞利珠单抗治疗。患者发现初始诊断1年后肿瘤和肺转移灶明显缩小，随后他入院接受手术治疗，目前已无病生存6个月。
